Ecological and demographic drivers of Oropouche virus transmission - Nature

If you’re a woman in your 40s, it’s time to think about osteoporosis. The bone disease may bring to mind an elderly patient, but the process that weakens the skeleton and makes a person vulnerable to bone fractures starts much earlier. Rapid bone loss begins two years before menopause, which happens at age 51 on average for women in the U. S., says Dr. Jocelyn Wittstein, an orthopedic surgeon at Duke Health in North Carolina and co-author of “The Complete Bone and Joint Health Plan: Help Prevent and Treat Osteoporosis and Arthritis.”“That sharp decline of bone loss happens a little earlier than most people realize it’s happening,” Wittstein tells TODAY.com. The main trigger for women is the midlife decline of estrogen because estrogen protects bones — it inhibits the cells that break them down, she notes. From two years before menopause to about a decade after it begins, the average woman loses 10% of her bone density, but there are things women can do to alter that trajectory, the doctor adds. “There is a tremendous amount of data pointing to the fact that this is preventable through exercise, diet and hormone therapy,” Wittstein says.

News|Articles|October 20, 2026 In a phase 1 trial, CD19/CD20/CD22 CAR T cells produced complete responses in 83% of patients with relapsed/refractory B-cell non-Hodgkin lymphoma. A trispecific chimeric antigen receptor (CAR) T-cell product targeting CD19, CD20, and CD22 with an OX40 costimulatory domain was safely administered to patients with relapsed/refractory B-cell malignancies, with particularly encouraging activity in B-cell non-Hodgkin lymphoma (B-NHL), according to results from a first-in-human phase 1 trial (NCT05418088) published in Blood Cancer Discovery. Successful manufacturing was achieved in 16 of 17 patients, with 1 failure occurring in a heavily pretreated patient with Richter transformation. The median manufacturing time was 7 days (range, 6-10), the median transduction efficiency was 38.8% (range, 16.9%-57.6%), and the median fold expansion was 5.4 (range, 1.4-12.9). No dose-limiting toxicities (DLTs) were observed across the 3 dose levels tested. Cytokine release syndrome (CRS) occurred in 25% of patients and was limited to grade 1 or 2, with a median onset of 8.5 days after infusion.